AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. RARE
  4. [Form 4] Ultragenyx Pharmaceutical Inc. Insider Trading Activity

[Form 4] Ultragenyx Pharmaceutical Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing reveals insider trading activity at Ultragenyx Pharmaceutical (RARE) by Director Corazon (Corsee) D. Sanders. On June 20, 2025, Sanders executed a significant sale of company shares:

  • Disposed of 2,405 shares at a price of $37.39 per share
  • Transaction value: approximately $89,873
  • Retained ownership: 15,344 shares held directly

This insider sale represents a notable reduction in Sanders' direct holdings in Ultragenyx. The transaction was executed as a standard sale (transaction code 'S') and was reported within the required SEC filing deadline. No derivative securities transactions were reported in this filing.

Il deposito del Modulo 4 rivela un'attivit脿 di insider trading presso Ultragenyx Pharmaceutical (RARE) da parte della Direttrice Corazon (Corsee) D. Sanders. Il 20 giugno 2025, Sanders ha effettuato una vendita significativa di azioni della societ脿:

  • Ha ceduto 2.405 azioni al prezzo di 37,39 $ per azione
  • Valore della transazione: circa 89.873 $
  • Detiene ancora: 15.344 azioni direttamente

Questa vendita da insider rappresenta una riduzione significativa delle partecipazioni dirette di Sanders in Ultragenyx. La transazione 猫 stata eseguita come vendita standard (codice transazione 'S') e riportata entro la scadenza prevista dalla SEC. Non sono state segnalate transazioni su strumenti derivati in questo deposito.

La presentaci贸n del Formulario 4 revela actividad de negociaci贸n interna en Ultragenyx Pharmaceutical (RARE) por parte de la Directora Corazon (Corsee) D. Sanders. El 20 de junio de 2025, Sanders realiz贸 una venta significativa de acciones de la compa帽铆a:

  • 痴别苍诲颈贸 2,405 acciones a un precio de $37.39 por acci贸n
  • Valor de la transacci贸n: aproximadamente $89,873
  • Propiedad retenida: 15,344 acciones en propiedad directa

Esta venta interna representa una reducci贸n notable en las participaciones directas de Sanders en Ultragenyx. La transacci贸n se realiz贸 como una venta est谩ndar (c贸digo de transacci贸n 'S') y se report贸 dentro del plazo requerido por la SEC. No se reportaron transacciones con valores derivados en esta presentaci贸n.

Form 4 鞝滌稖靹滊電� Ultragenyx Pharmaceutical (RARE)鞚� 鞚挫偓 Corazon (Corsee) D. Sanders鞚� 雮措秬鞛� 瓯半灅 頇滊彊鞚� 氤挫棳欷嶋媹雼�. 2025雲� 6鞗� 20鞚�, Sanders電� 須岇偓 欤检嫕鞚� 雽�攴滊搿� 毵る弰頄堨姷雼堧嫟:

  • 2,405欤�毳� 欤茧嫻 $37.39鞐� 觳橂秳
  • 瓯半灅 旮堨暋: 鞎� $89,873
  • 歆侅爲 氤挫湢 欤检嫕: 15,344欤� 鞙犾 欷�

鞚措矆 雮措秬鞛� 毵る弰電� Sanders鞚� Ultragenyx 歆侅爲 氤挫湢 欤检嫕鞚� 靸侂嫻頌� 欷勳柎霌� 瓴冹潉 鞚橂頃╇媹雼�. 瓯半灅電� 響滌 毵る弰(瓯半灅 旖旊摐 'S')搿� 鞁ろ枆霅橃棃鞙茧┌, SEC 鞝滌稖 旮绊暅 雮挫棎 氤搓碃霅橃棃鞀惦媹雼�. 鞚措矆 鞝滌稖靹滊鞐愲姅 韺岇儩靸來拡 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

Le d茅p么t du formulaire 4 r茅v猫le une activit茅 d鈥檌niti茅 chez Ultragenyx Pharmaceutical (RARE) par la directrice Corazon (Corsee) D. Sanders. Le 20 juin 2025, Sanders a effectu茅 une vente importante d鈥檃ctions de la soci茅t茅 :

  • 础濒颈茅苍茅 2 405 actions au prix de 37,39 $ par action
  • Valeur de la transaction : environ 89 873 $
  • Participation restante : 15 344 actions d茅tenues directement

Cette vente d鈥檌niti茅 repr茅sente une r茅duction notable des parts directes de Sanders dans Ultragenyx. La transaction a 茅t茅 r茅alis茅e comme une vente standard (code transaction 'S') et a 茅t茅 d茅clar茅e dans les d茅lais requis par la SEC. Aucune transaction sur titres d茅riv茅s n鈥檃 茅t茅 signal茅e dans ce d茅p么t.

Die Einreichung des Formulars 4 zeigt Insider-Handelsaktivit盲ten bei Ultragenyx Pharmaceutical (RARE) durch die Direktorin Corazon (Corsee) D. Sanders. Am 20. Juni 2025 f眉hrte Sanders einen bedeutenden Verkauf von Unternehmensaktien durch:

  • 痴别谤盲耻脽别谤迟别 2.405 Aktien zu einem Preis von 37,39 $ pro Aktie
  • Transaktionswert: ca. 89.873 $
  • Verbleibender Besitz: 15.344 Aktien im Direktbesitz

Dieser Insider-Verkauf stellt eine deutliche Reduzierung von Sanders鈥� Direktbeteiligungen an Ultragenyx dar. Die Transaktion wurde als Standardverkauf (Transaktionscode 'S') ausgef眉hrt und fristgerecht bei der SEC gemeldet. Es wurden keine Derivatgesch盲fte in dieser Meldung angegeben.

Positive
  • None.
Negative
  • Director Corsee Sanders sold 2,405 shares at $37.39 per share (approximately $89,900 total value), retaining 15,344 shares

Il deposito del Modulo 4 rivela un'attivit脿 di insider trading presso Ultragenyx Pharmaceutical (RARE) da parte della Direttrice Corazon (Corsee) D. Sanders. Il 20 giugno 2025, Sanders ha effettuato una vendita significativa di azioni della societ脿:

  • Ha ceduto 2.405 azioni al prezzo di 37,39 $ per azione
  • Valore della transazione: circa 89.873 $
  • Detiene ancora: 15.344 azioni direttamente

Questa vendita da insider rappresenta una riduzione significativa delle partecipazioni dirette di Sanders in Ultragenyx. La transazione 猫 stata eseguita come vendita standard (codice transazione 'S') e riportata entro la scadenza prevista dalla SEC. Non sono state segnalate transazioni su strumenti derivati in questo deposito.

La presentaci贸n del Formulario 4 revela actividad de negociaci贸n interna en Ultragenyx Pharmaceutical (RARE) por parte de la Directora Corazon (Corsee) D. Sanders. El 20 de junio de 2025, Sanders realiz贸 una venta significativa de acciones de la compa帽铆a:

  • 痴别苍诲颈贸 2,405 acciones a un precio de $37.39 por acci贸n
  • Valor de la transacci贸n: aproximadamente $89,873
  • Propiedad retenida: 15,344 acciones en propiedad directa

Esta venta interna representa una reducci贸n notable en las participaciones directas de Sanders en Ultragenyx. La transacci贸n se realiz贸 como una venta est谩ndar (c贸digo de transacci贸n 'S') y se report贸 dentro del plazo requerido por la SEC. No se reportaron transacciones con valores derivados en esta presentaci贸n.

Form 4 鞝滌稖靹滊電� Ultragenyx Pharmaceutical (RARE)鞚� 鞚挫偓 Corazon (Corsee) D. Sanders鞚� 雮措秬鞛� 瓯半灅 頇滊彊鞚� 氤挫棳欷嶋媹雼�. 2025雲� 6鞗� 20鞚�, Sanders電� 須岇偓 欤检嫕鞚� 雽�攴滊搿� 毵る弰頄堨姷雼堧嫟:

  • 2,405欤�毳� 欤茧嫻 $37.39鞐� 觳橂秳
  • 瓯半灅 旮堨暋: 鞎� $89,873
  • 歆侅爲 氤挫湢 欤检嫕: 15,344欤� 鞙犾 欷�

鞚措矆 雮措秬鞛� 毵る弰電� Sanders鞚� Ultragenyx 歆侅爲 氤挫湢 欤检嫕鞚� 靸侂嫻頌� 欷勳柎霌� 瓴冹潉 鞚橂頃╇媹雼�. 瓯半灅電� 響滌 毵る弰(瓯半灅 旖旊摐 'S')搿� 鞁ろ枆霅橃棃鞙茧┌, SEC 鞝滌稖 旮绊暅 雮挫棎 氤搓碃霅橃棃鞀惦媹雼�. 鞚措矆 鞝滌稖靹滊鞐愲姅 韺岇儩靸來拡 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

Le d茅p么t du formulaire 4 r茅v猫le une activit茅 d鈥檌niti茅 chez Ultragenyx Pharmaceutical (RARE) par la directrice Corazon (Corsee) D. Sanders. Le 20 juin 2025, Sanders a effectu茅 une vente importante d鈥檃ctions de la soci茅t茅 :

  • 础濒颈茅苍茅 2 405 actions au prix de 37,39 $ par action
  • Valeur de la transaction : environ 89 873 $
  • Participation restante : 15 344 actions d茅tenues directement

Cette vente d鈥檌niti茅 repr茅sente une r茅duction notable des parts directes de Sanders dans Ultragenyx. La transaction a 茅t茅 r茅alis茅e comme une vente standard (code transaction 'S') et a 茅t茅 d茅clar茅e dans les d茅lais requis par la SEC. Aucune transaction sur titres d茅riv茅s n鈥檃 茅t茅 signal茅e dans ce d茅p么t.

Die Einreichung des Formulars 4 zeigt Insider-Handelsaktivit盲ten bei Ultragenyx Pharmaceutical (RARE) durch die Direktorin Corazon (Corsee) D. Sanders. Am 20. Juni 2025 f眉hrte Sanders einen bedeutenden Verkauf von Unternehmensaktien durch:

  • 痴别谤盲耻脽别谤迟别 2.405 Aktien zu einem Preis von 37,39 $ pro Aktie
  • Transaktionswert: ca. 89.873 $
  • Verbleibender Besitz: 15.344 Aktien im Direktbesitz

Dieser Insider-Verkauf stellt eine deutliche Reduzierung von Sanders鈥� Direktbeteiligungen an Ultragenyx dar. Die Transaktion wurde als Standardverkauf (Transaktionscode 'S') ausgef眉hrt und fristgerecht bei der SEC gemeldet. Es wurden keine Derivatgesch盲fte in dieser Meldung angegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sanders Corazon (Corsee) D.
(Last) (First) (Middle)
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT
(Street)
NOVATO CA 94949
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 S 2,405 D $37.39 15,344 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Karah Parschauer, attorney-in-fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many shares of RARE stock did Director Sanders sell on June 20, 2025?

Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical Inc. (RARE) common stock on June 20, 2025.

What was the selling price of RARE shares in Director Sanders' transaction?

The shares were sold at a price of $37.39 per share.

How many RARE shares does Director Sanders own after the June 2025 sale?

Following the reported transaction, Director Sanders directly owns 15,344 shares of Ultragenyx Pharmaceutical Inc. (RARE) common stock.

What type of ownership does Director Sanders have in RARE stock?

Director Sanders has direct ownership (D) of the RARE shares, with no reported indirect ownership positions disclosed in the Form 4 filing.

When was the Form 4 for RARE insider trading filed with the SEC?

The Form 4 was filed with the SEC on June 28, 2025, reporting a transaction that occurred on June 20, 2025. The form was signed by Karah Parschauer as attorney-in-fact on June 23, 2025.
Stock RARE logo
Ultragenyx Pharm

NASDAQ:RARE

RARE Rankings

#2152 Ranked by Market Cap
N/A Ranked by Dividends
#5 Top Loser

RARE Latest News

Jul 9, 2025
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
Jun 27, 2025
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
Jun 20, 2025
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jun 3, 2025
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
May 20, 2025
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE Latest SEC Filings

Jul 9, 2025
[8-K] Ultragenyx Pharmaceutical Inc. Reports Material Event
Jun 27, 2025
[8-K] Ultragenyx Pharmaceutical Inc. Reports Material Event
Jun 20, 2025
[144] Ultragenyx Pharmaceutical Inc. SEC Filing

RARE Stock Data

3.43B
90.51M
3.65%
98.31%
4.96%
Biotechnology
Pharmaceutical Preparations
United States
NOVATO